Cellnovo Group (Paris:CLNV) (“Cellnovo” or the “Company” CLNV:EN Paris), a medical technology company marketing the first connected diabetes management platform based on a locked-down AndroidTM¬†smartphone communicating via Bluetooth¬†with a small, discreet micro-pump, today announces the signature of a distribution agreement in Colombia with Diabetrics, a leading distributor of pharmaceuticals and medical devices.
Diabetrics, a subsidiary of Procaps Group, specializes in integrated solutions for people with diabetes and is the national leader in the commercialization of blood glucose monitors (BGMs) and post-sales technical support. The process for registration to allow the commercialization of the Cellnovo System in Colombia is underway, and the Company anticipates its first sales in Q2 2019. Cellnovo will be the first and only micro-pump available in the country. Colombia is the largest insulin pump market in South America with an advanced healthcare system.
Sophie Baratte, Chief Executive Officer of Cellnovo, commented¬†”We continue to build our international network of distribution partners in markets where there is a clear demand for our unique insulin pump and this agreement in Colombia opens the door to a new continent, South America. We are pleased to be able to leverage the strength of an established and recognized player, Diabetrics, and we look forward to expanding on this strong foundation to increase the availability of the Cellnovo System around the world.”
Alain Cortesi, Vice President of Corporate Development, Procaps Group, said:¬†“We are proud to help Cellnovo to meet the high demand of type 1 diabetes patients for an insulin pump in Colombia. The Cellnovo System is one of the most advanced products on the market in terms of technology, reliability, and comfort for patients, so they were the natural choice for us. We are pleased to be able to offer the Cellnovo System as the first and only insulin micro-pump in the Colombian market.”
